Answers are grounded in this paper and cite their sources.
Our results suggested that reduced expression of miR-130a may be involved in the paclitaxel-resistance and that miR-130a could be a therapeutic target for taxane-resistant prostate cancer patients.
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: